![](https://investorshub.advfn.com/uicon/666640.png?cb=1632484749)
Monday, July 29, 2019 12:47:44 PM
Meet Our CaverStem®Team! Call Us Today for More Information or Simply Request an Appointment Online. We Are Ready to Help You Feel Better!
Timothy Warbington
CEO
Mr. Warbington has over 25 years of executive level management and ownership experience. Mr. Warbington has been a lifescience investor for over 12 years. Since 2011 he has been the CEO of Creative Medical Health, Inc. and Creative Medical Technology Holdings, Inc., a public company and since 2012, CEO of iBiologics, a spin off from the University of Utah. In connection with this experience, he has built a network of scientists, physicians and executives to participate as executive officers and directors of CMH.
Donald Dickerson MBA
CFO
Mr. Dickerson has a Masters of Business Administration, Finance from the University of Southern California. Mr. Dickerson has worked in a number of management and accounting positions and has experience with companies in the technology, manufacturing and health sciences area. Mr. Dickerson’s experience includes leadership positions at BioRasi, Dell, Boeing Capital and Medistem, Inc.
Annette Marleau Phd
Chief Scientific Officer
Prior to joining CMH, Dr. Marleau was the Director of Tumor Immunology at Aethlon Medical Inc. Dr. Marleau has a PhD in Immunology from the University of Western Ontario as well as a MS in Reproductive Immunology from Ontario Veterinary Collateral, University of Guelph, Canada and a BS in Biology from the University of Waterloo, Canada.
Thomas Ichim PhD
President Biotechnology Division
Dr. Ichim has 20 years experience in the biotechnology industry, having served as the Vice President of Cellular Therapies, Intrexon, Inc. Dr. Ichim is an accomplished inventor and was the President and Chief Scientific Officer at Medistem, Inc., a recently acquired publicly traded company. Dr. Ichim has a PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat, a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada and a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada. Dr. Ichim has written over 100 peer reviewed publications and has founded and operated successful biotech companies in the past.
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM